INVESTOR RELATIONS
CEO comment
November 12
“With a solid evidence platform and supported by strong partnerships, we put the final pieces of the puzzle into place during the third quarter for the design of the clinical study that will evaluate our drug candidate arfolitixorin as a new potential component in the treatment of colorectal cancer. Few drug candidates in the clinical development phase that we are in have as broad a scientific base as arfolitixorin – and all new data, from preclinical studies to analyses of the previous phase III study AGENT, indicate that the new study design offers greater possibilities for arfolitixorin to demonstrate its full potential,“ says CEO, Petter Segelman Lindqvist.
INVESTORS – latest reports and presentations
Media – Lates pressreleases
Isofol Medical AB (publ) publishes interim report, January–September 2024
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is…
Isofol announces that an abstract has been accepted for presentation at ASCO GI 2025
GOTHENBURG, SWEDEN, November 11, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announces that an abstract with results from a post hoc-analysis…
Isofol invites to investor meeting on November 20, 2024
GOTHENBURG, Sweden, October 25, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present…
SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS
About arfolitixorin
Want to know more about the the drug candidate arfolitxorin?
Last updated 11-12-2024